Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia

Maximal androgen blockade the prime prostate cancer treatment option in older patients
16 Sep 2022
Among prostate cancer patients aged ≥75 years, maximal androgen blockage (MAB) appears to be the most common treatment option, reports a new South Korea study. Meanwhile, the combination of leuprolide and bicalutamide is the most common MAB regimen.
16 Sep 2022

First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
15 Sep 2022
bởiRoshini Claire Anthony
First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.
15 Sep 2022






